In this study, volunteer patients were randomized into one of two experiment
groups: 14 patients received an experimental vaccine or 6 patients received
a placebo vaccine. Nineteen weeks later, all 20 patients were exposed to a
drug-sensitive malaria virus strain; the motivation of using a
drug-sensitive strain of virus here is for ethical considerations, allowing
any infections to be treated effectively.